Proposed FDA ad rule could cripple drug commercials and test free-speech limits
The FDA’s draft rule would force DTC drug ads to include extensive safety disclosures, dramatically raising costs and prompting constitutional concerns.
The Food and Drug Administration is set to issue a rule titled “Transparency in Direct-to-Consumer Advertising,” which would require every prescription-drug commercial to read an exhaustive list of risk, contraindication and safety statements. This requirement would expand a 30-second ad to several minutes, inflating costs dramatically; the agency projects more than $100 million in first-year expenses, yet a Super Bowl spot could exceed $48 million.
Advocacy group Public Citizen and progressive legislators Bernie Sanders and Ilhan Omar have pushed for an outright ban on such ads, citing consumer protection goals. Critics warn the rule is a backdoor method of silencing speech by making it financially untenable, potentially setting a precedent for other industries. Supreme Court precedents such as Virginia Pharmacy, Central Hudson, and Zauderer suggest the regulation may fail constitutional scrutiny. The article argues the FDA should withdraw the proposal before it is used to target lawful businesses beyond pharmaceuticals.
Why it matters
The rule could shut down drug advertising and set a precedent for restricting commercial speech across industries.
In this story
